Home > Publications database > Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients. > print

001     301766
005     20250829094217.0
024 7 _ |a 10.1200/JCO-24-02776
|2 doi
024 7 _ |a pmid:40460331
|2 pmid
024 7 _ |a 0732-183X
|2 ISSN
024 7 _ |a 1527-7755
|2 ISSN
024 7 _ |a altmetric:177738189
|2 altmetric
037 _ _ |a DKFZ-2025-01146
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lodde, Georg C
|0 0000-0002-6930-2694
|b 0
245 _ _ |a Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients.
260 _ _ |a Alexandria, Va.
|c 2025
|b American Society of Clinical Oncology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756452925_12784
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Sep;43(25):2793-2805
520 _ _ |a Adjuvant treatment with immune checkpoint inhibition (PD1) and targeted therapy (TT) with BRAF+MEK inhibitors significantly improved recurrence-free survival (RFS) of stage III melanoma patients. We investigated efficacy of adjuvant therapy with PD1 or TT under real-world conditions.A total of 589 stage III melanoma patients who started adjuvant PD1 or TT between June 2018 and September 2019 from 11 major German Dermatologic Cooperative Oncology Group (DeCOG) skin cancer centers were followed for 4 years. Endpoints were RFS, overall (OS) and melanoma-specific survival (MSS). Survival analyses and adjusted hazard ratios (HRs) were estimated with Kaplan-Meier and Cox proportional hazards model, inverse probability treatment weighting and propensity score matching.RFS at 48 months was 42.9% (95% CI 38.5-47.8) for all PD1 patients and 52.6% (95% CI 43.6-63.3) for TT patients. Among BRAF-mutated patients, rate of recurrence was higher for PD1 compared to TT (HR 1.57, 95% CI 1.09-2.26). OS at 4 years was 80.8% [95%CI 73.6-88.7] for BRAF-mutated PD1 patients and 87.3% [95%CI 81.0-94.0]) for TT patients. Patients starting adjuvant PD1 after resection of macroscopic lymph node metastases had a higher risk of rapid recurrence (1-year RFS all PD1 58%) compared to 87% in TT patients. Rate of recurrence after premature discontinuation (≤6 vs. >6 months treatment) was higher in TT patients (HR 1.47, 95% CI 0.67-3.23), but not in PD1 patients (HR 1.07, 95% CI 0.73-1.55).BRAF-mutated PD1 patients had a markedly higher rate of relapse compared to TT patients. Rapid recurrences occured particulary in PD1-treated patients with prior macroscopic lymph node metastasis. Treatment duration shorter than 6 months did not negatively impact RFS in PD1, but in TT patients.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Hassel, Jessica C
|b 1
700 1 _ |a von Wasielewski, Imke
|b 2
700 1 _ |a Meier, Friedegund
|0 0000-0003-4340-9706
|b 3
700 1 _ |a Mohr, Peter
|b 4
700 1 _ |a Kähler, Katharina
|b 5
700 1 _ |a Hauschild, Axel
|b 6
700 1 _ |a Glutsch, Valerie
|b 7
700 1 _ |a Stege, Henner
|b 8
700 1 _ |a Berking, Carola
|0 0000-0003-0229-8931
|b 9
700 1 _ |a Hüning, Svea
|b 10
700 1 _ |a Huynh, Julia
|0 0000-0002-2357-4184
|b 11
700 1 _ |a Gutzmer, Ralf
|0 0000-0001-7921-2820
|b 12
700 1 _ |a Reinhardt, Lydia
|b 13
700 1 _ |a Schilling, Bastian
|0 0000-0001-8859-4103
|b 14
700 1 _ |a Loquai, Carmen
|b 15
700 1 _ |a Erdmann, Michael
|0 0000-0001-7136-6489
|b 16
700 1 _ |a Stang, Andreas
|0 0000-0001-6363-9061
|b 17
700 1 _ |a Kowall, Bernd
|b 18
700 1 _ |a Galetzka, Wolfgang
|b 19
700 1 _ |a Roesch, Alexander
|b 20
700 1 _ |a Tilkorn, Daniel
|b 21
700 1 _ |a Ugurel, Selma
|0 0000-0002-9384-6704
|b 22
700 1 _ |a Zimmer, Lisa
|0 0000-0002-3680-3521
|b 23
700 1 _ |a Schadendorf, Dirk
|0 0000-0003-3524-7858
|b 24
700 1 _ |a Forschner, Andrea
|b 25
700 1 _ |a Livingstone, Elisabeth
|0 0000-0001-8279-9239
|b 26
773 _ _ |a 10.1200/JCO-24-02776
|g p. 10.1200/JCO-24-02776
|0 PERI:(DE-600)2005181-5
|n 25
|p 2793-2805
|t Journal of clinical oncology
|v 43
|y 2025
|x 0732-183X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:301766
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 0000-0003-3524-7858
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN ONCOL : 2022
|d 2025-01-06
915 _ _ |a IF >= 40
|0 StatID:(DE-HGF)9940
|2 StatID
|b J CLIN ONCOL : 2022
|d 2025-01-06
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21